Author

M. D. Minden

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 9 Cell Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 11 Assay:bulk RNA-seq· 7 Approach:experimental assay· 6 Research Focus:cell type annotation· 5 Research Focus:differential expression· 5 Research Focus:cancer & tumor microenvironment· 4 Approach:statistical model· 4 Research Focus:drug response / drug discovery· 3

Frequent Co-Authors

J. E. Dick· 6 shared J. A. Kennedy· 4 shared A. G. X. Zeng· 3 shared A. Mitchell· 3 shared A. Arruda· 2 shared A. Murison· 2 shared D. Barsyte-Lovejoy· 2 shared E. M. Schoof· 2 shared

Activity by Year

2019-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersCancer Biology

J. E. Dick

Mutual co-authors in cluster

Author profile →

11 papers

Recent·Most cited

Single-cell transcriptional mapping reveals genetic and non-genetic determinants of aberrant differentiation in AML

A. G. X. Zeng, I. Iacobucci, S. Shah, A. Mitchell, G. Wong, S. Bansal, D. Chen, Q. Gao, H. Kim, J. A. Kennedy, M. D. Minden, T. Haferlach, C. G. Mullighan, J. E. Dick

The paper constructs a reference atlas of human hematopoiesis and maps AML differentiation patterns, revealing genetic and non-genetic factors driving aberrant differentiation in leukemia.

bioRxiv · Dec 26, 2023Cancer Biology

Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutations

M. Alqazzaz, G. Luciani, V. Vu, R. M. Machado, M. M. Szewczyk, E. C. Adamson, S. Cheon, C. Arrowsmith, M. D. Minden, D. Barsyte-Lovejoy

This study identifies epigenetic vulnerabilities in AML and MDS/MPN with EZH2 mutations, showing increased sensitivity to EZH2 and EED inhibitors and upregulation of cell death pathways.

bioRxiv · Nov 20, 2023Cancer Biology

KDM6A loss sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition

L. D. Boila, S. Ghosh, S. K. Bandyopadhyay, L. Jin, A. Murison, A. G. X. Zeng, W. Shaikh, S. Bhowmik, S. S. N. A. Muddineni, M. Biswas, S. Sinha, S. S. Chatterjee, N. Mbong, O. I. Gan, A. Bose, , A. Sengupta

This study shows that KDM6A loss in AML increases sensitivity to PARP and BCL2 inhibitors, suggesting a new combination therapy approach for KDM6A-mutant AML.

bioRxiv · Jul 12, 2022 · PreprintCancer Biology

A two-step in vivo CRISPR screen unveils pervasive RNA binding protein dependencies for leukemic stem cells and identifies ELAVL1 as a therapeutic target

A. Vujovic, L. P. M. H. de Rooij, A. Keyvani Chahi, H. T. Chen, B. Yee, S. K. Loganathan, L. Liu, D. C. H. Chan, A. Tajik, E. Tsao, S. Moreira, P. Joshi, J. Xu, N. Wong, S. Zandi, , K. J. Hope

This study identifies RNA binding proteins essential for leukemic stem cell survival using an in vivo CRISPR screen and highlights ELAVL1 as a therapeutic target in AML.

bioRxiv · Jun 11, 2022 · PreprintCancer Biology

PRMT5 regulates ATF4 transcript splicing and oxidative stress response

M. M. Szewczyk, G. M. Luciani, V. Vu, A. Murison, D. Dilworth, M. Lupien, C. H. Arrowsmith, M. D. Minden, D. Barsyte-Lovejoy

This study shows PRMT5 regulates ATF4 splicing and oxidative stress response in AML, with EVI1-high cells depending on PRMT5 for redox balance.

bioRxiv · Feb 2, 2022Cancer Biology

A cellular hierarchy framework for understanding heterogeneity and predicting drug response in AML

A. G. X. Zeng, S. Bansal, L. Jin, A. Mitchell, W. C. Chen, H. A. Abbas, M. Chan-Seng-Yue, V. Voisin, P. van Galen, A. Tierens, M. Cheok, C. Preudhomme, H. Dombret, N. Daver, P. A. Futreal, , J. E. Dick

This study identifies a cellular hierarchy framework in AML that links disease heterogeneity with drug response and develops a 7-gene biomarker predictive of drug sensitivity.

bioRxiv · Jan 25, 2022Cancer Biology

Identification of the Global miR-130a Targetome Reveals a Novel Role for TBL1XR1 in Hematopoietic Stem Cell Self-Renewal and t(8;21) AML

G. Krivdova, V. Voisin, E. M. Schoof, S. A. Marhon, A. J. Murison, J. L. McLeod, M. Gabra, A. G. Zeng, E. L. Van Nostrand, S. J. Aigner, A. A. Shishkin, B. A. Yee, K. G. Hermans, A. G. Trotman-Grant, N. Mbong, , E. R. Lechman

This study identifies miR-130a as a regulator of HSC self-renewal and differentiation, with TBL1XR1 as a key target, and shows its role in maintaining the oncogenic program in t(8;21) AML.

bioRxiv · Jul 30, 2021Cell Biology

Pseudo-mutant p53 as a targetable phenotype of DNMT3A-mutated pre-leukemia

A. Tuval, Y. Brilon, H. Ezogy, Y. Moskovitz, T. Biezuner, D. Leshkowitz, T. M. Salame, M. D. Minden, P. Tal, V. Rotter, M. Oren, N. Kaushansky, L. I. Shlush

The paper identifies a pseudomutant p53 conformation in DNMT3A-mutated pre-leukemic HSPCs and shows that shifting to the wild-type conformation can eliminate these cells.

bioRxiv · May 30, 2021 · PreprintCancer Biology

INPP4B drives lysosome biogenesis to restrict leukemic stem cell differentiation and promote leukemogenesis

J. F. Woolley, K. Chen, G. T. Saffi, G. E. Genc, D. K. C. Lee, I. Dzneladze, R. He, J. T.-S. Chow, M. M. Gabra, M. H. Son, C. M. P. Melo, C. A. Newell, A. He, E. M. Schoof, S. Z. Xie, , L. Salmena

This study identifies INPP4B's role in promoting leukemic stem cell (LSC) survival by enhancing lysosome biogenesis, leading to poor AML prognosis and suggesting therapeutic targets.

bioRxiv · Mar 25, 2021 · PreprintCancer Biology

Repression of LKB1 by miR-17~92 sensitizes MYC-dependent lymphoma to biguanide treatment

S. Izreig, A. Gariepy, A. O. Donayo, G. Bridon, D. Avizonis, R. D. Sheldon, R. Laister, M. D. Minden, N. A. Johnson, K. S. Williams, M. S. Rudoltz, T. F. Duchaine, S. Yoo, M. N. Pollak, R. G. Jones

The paper shows that miR-17~92 expression in Myc+ tumors increases sensitivity to biguanide treatment by disrupting bioenergetic stability in lymphoma cells.

bioRxiv · Dec 20, 2019Cancer Biology

Immune Landscapes Predict Chemotherapy Resistance And Immunotherapy Response In Acute Myeloid Leukemia

J. Vadakekolathu, M. D. Minden, T. Hood, S. E. Church, S. Reeder, H. Altmann, A. H. Sullivan, E. J. Viboch, T. Patel, N. Ibrahimova, S. E. Warren, A. Arruda, Y. Liang, J. Muth, M. Schmitz, , S. Rutella

This study identifies immune subtypes in AML and shows that IFN-gamma profiles predict chemotherapy resistance and immunotherapy response.

bioRxiv · Jul 26, 2019Immunology